IN2015DN02233A - - Google Patents

Info

Publication number
IN2015DN02233A
IN2015DN02233A IN2233DEN2015A IN2015DN02233A IN 2015DN02233 A IN2015DN02233 A IN 2015DN02233A IN 2233DEN2015 A IN2233DEN2015 A IN 2233DEN2015A IN 2015DN02233 A IN2015DN02233 A IN 2015DN02233A
Authority
IN
India
Prior art keywords
dendrimer
macromolecule
eye
salt
generations
Prior art date
Application number
Other languages
English (en)
Inventor
Jacinth Kincaid; Fairley
Colin Paul; Barrett
Jeremy Robert Arthur; Paull
Original Assignee
Starpharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Starpharma Pty Ltd filed Critical Starpharma Pty Ltd
Publication of IN2015DN02233A publication Critical patent/IN2015DN02233A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/795Polymers containing sulfur
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN2233DEN2015 2012-09-13 2013-09-13 IN2015DN02233A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261700714P 2012-09-13 2012-09-13
PCT/US2013/059810 WO2014043576A1 (en) 2012-09-13 2013-09-13 Method of treatment or prophylaxis of infections of the eye

Publications (1)

Publication Number Publication Date
IN2015DN02233A true IN2015DN02233A (enExample) 2015-08-21

Family

ID=50278734

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2233DEN2015 IN2015DN02233A (enExample) 2012-09-13 2013-09-13

Country Status (9)

Country Link
US (2) US10149885B2 (enExample)
EP (1) EP2895161B1 (enExample)
JP (2) JP6419701B2 (enExample)
CN (2) CN105007910B (enExample)
CA (1) CA2884897C (enExample)
DK (1) DK2895161T3 (enExample)
ES (1) ES2633778T3 (enExample)
IN (1) IN2015DN02233A (enExample)
WO (1) WO2014043576A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8974825B2 (en) * 2007-07-06 2015-03-10 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
RU2667118C1 (ru) * 2017-11-15 2018-09-14 Федеральное государственное бюджетное научное учреждение "Прикаспийский зональный научно-исследовательский ветеринарный институт" Универсальное средство в виде мази для комплексного лечения глазных болезней животных и способ его получения
CN110664757B (zh) * 2018-11-19 2022-08-02 成都瑞沐生物医药科技有限公司 纳米晶滴眼剂、其制备方法及其应用
SG11202112332VA (en) * 2020-04-15 2021-12-30 Starpharma Pty Ltd Method of prophylaxis of coronavirus and/or respiratory syncytial virus infection

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM623994A0 (en) * 1994-06-15 1994-07-07 Biomolecular Research Institute Limited Antiviral dendrimers
SK20332000A3 (sk) * 1998-07-14 2001-05-10 Pharmacia & Upjohn Použitie oxazolidinónov
AUPP584298A0 (en) 1998-09-14 1998-10-08 Starpharma Limited Antimicrobial and antiparasitic agents
AUPR412801A0 (en) * 2001-03-30 2001-05-03 Starpharma Limited Agent for the prevention and treatment of sexually transmitted disease s - I
WO2005007223A2 (en) * 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
CA2562356A1 (en) * 2004-04-08 2005-10-27 Retmed Pty Ltd Treatment of ophthalmic conditions with mineralcorticoids
MX2008005048A (es) 2005-10-18 2008-11-18 Starpharma Pty Ltd Sistema de suministro de composicion microbicidal de dendrimero.
CA2626865C (en) * 2005-10-25 2014-12-30 Starpharma Pty Limited Macromolecular compounds having controlled stoichiometry
EP2040721B1 (en) * 2006-05-31 2013-05-08 Medihoney Pty Ltd Medicinal compositions containing honey
EP2214646B1 (en) 2007-10-05 2021-06-23 Wayne State University Dendrimers for sustained release of compounds
BRPI1008602A8 (pt) * 2009-02-18 2018-01-02 Eyeon Particle Sciences Llc uso de co-polímero bi-funcional para as aplicações oftálmicas e outras aplicações tópicas e locais
BR112012000381A2 (pt) 2009-07-07 2016-03-29 Adenovir Pharma Ab novos compostos antivirais úteis para o tratamento ou prevenção de queratoconjuntivite epidêmica
PT2709633T (pt) 2011-05-16 2019-11-18 Starpharma Pty Ltd Método de tratamento ou profilaxia da vaginose bacteriana

Also Published As

Publication number Publication date
US11219691B2 (en) 2022-01-11
CN105007910A (zh) 2015-10-28
JP2019001827A (ja) 2019-01-10
CA2884897C (en) 2021-07-27
US20190070249A1 (en) 2019-03-07
JP6419701B2 (ja) 2018-11-07
HK1212619A1 (en) 2016-06-17
JP2015528509A (ja) 2015-09-28
EP2895161A1 (en) 2015-07-22
EP2895161A4 (en) 2016-03-23
US10149885B2 (en) 2018-12-11
CA2884897A1 (en) 2014-03-20
ES2633778T3 (es) 2017-09-25
CN108452316B (zh) 2022-04-15
US20150238557A1 (en) 2015-08-27
JP6766114B2 (ja) 2020-10-07
WO2014043576A1 (en) 2014-03-20
CN105007910B (zh) 2019-03-19
CN108452316A (zh) 2018-08-28
DK2895161T3 (en) 2017-08-21
EP2895161B1 (en) 2017-05-03

Similar Documents

Publication Publication Date Title
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
EA201201648A1 (ru) Стимуляторы sgc
MX2015008187A (es) Inhibidores de alk deuterados.
NZ607600A (en) Compositions for the treatment of diseases
MX349159B (es) Derivados deuterados de ivacaftor.
PH12020551986A1 (en) Syk inhibitors
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
HK1212207A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
NZ715747A (en) Syk inhibitors
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
EA201591743A8 (ru) СТИМУЛЯТОРЫ sGC
MY161233A (en) Bis (fluoroalkyl)-1, 4-benzodiazepinone compounds
MA33939B1 (fr) 5-alcynyl-pyrimidines
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
EA201691044A1 (ru) Новый октагидро-циклобута[1,2-c;3,4-c']дипиррол-2-ил
EA201892726A1 (ru) Дейтерированный палбоциклиб
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
MX2015009696A (es) Composiciones estables que comprenden heparinoide, anestesico de accion aguda y regulador de ph.
MX361642B (es) Composiciones antisépticas catiónicas.
MX2015015755A (es) Derivados de perhidroquinoxalina utiles como analgesicos.
MX359069B (es) Sal y formas cristalinas de inhibidor de quinasa tipo polo-4.
EA201391586A1 (ru) ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ